• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Memory impairment   pipeline review, h1 2013 - Reports Corner
 

Memory impairment pipeline review, h1 2013 - Reports Corner

on

  • 377 views

Global Markets Direct's, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development ...

Global Markets Direct's, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/15464/Memory-Impairment---Pipeline-Review,-H1-2013/

Statistics

Views

Total Views
377
Views on SlideShare
377
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Memory impairment   pipeline review, h1 2013 - Reports Corner Memory impairment pipeline review, h1 2013 - Reports Corner Presentation Transcript

    • RCReports CornerMemory Impairment - Pipeline Review, H1 2013
    • DescriptionDescriptionReports Cornerwww.reportscorner.comGlobal Markets Directs, Memory Impairment - Pipeline Review,H1 2013, provides an overview of the indications therapeuticpipeline. This report provides information on the therapeuticdevelopment for Memory Impairment, complete with latestupdates, and special features on late-stage and discontinuedprojects.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comGlobal Markets Directs, Memory Impairment - Pipeline Review,H1 2013, provides an overview of the indications therapeuticpipeline. This report provides information on the therapeuticdevelopment for Memory Impairment, complete with latestupdates, and special features on late-stage and discontinuedprojects. It also reviews key players involved in the therapeuticdevelopment for Memory Impairment. Memory Impairment -Pipeline Review, Half Year is built using data and informationsourced from Global Markets Directs proprietary databases,Company/University websites, SEC filings, investor presentationsand featured press releases from company/university sites andindustry-specific third party sources, put together by GlobalMarkets Directs team.Note*: Certain sections in the report may beremoved or altered based on the availability and relevance of datafor the indicated disease.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comScope- A snapshot of the global therapeutic scenario for MemoryImpairment.- A review of the Memory Impairment products underdevelopment by companies and universities/research institutesbased on information derived from company and industry-specificsources.- Coverage of products based on various stages ofdevelopment ranging from discovery till registration stages.- Afeature on pipeline projects on the basis of monotherapy andcombined therapeutics.- Coverage of the Memory Impairmentpipeline on the basis of route of administration and moleculetype.- Key discontinued pipeline projects.- Latest news and dealsrelating to the products.Reasons to buy- Identify and understandimportant and diverse types of therapeutics under developmentfor Memory Impairment.- Identify emerging players with potentiallystrong product portfolio and design effective counter-strategies togain competitive advantage.-
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comPlan mergers and acquisitions effectively by identifying players ofthe most promising pipeline.- Devise corrective measures forpipeline projects by understanding Memory Impairment pipelinedepth and focus of Indication therapeutics.- Develop and designin-licensing and out-licensing strategies by identifyingprospective partners with the most attractive projects to enhanceand expand business potential and scope.- Modify the therapeuticportfolio by identifying discontinued projects and understandingthe factors that drove them from pipeline.
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comTable of ContentsTable of Contents 2List of Tables 5List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Memory Impairment Overview 7Therapeutics Development 8An Overview of Pipeline Products for Memory Impairment 8Memory Impairment Therapeutics under Development by Companies 10Memory Impairment Therapeutics under Investigation by Universities/Institutes 11Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comComparative Analysis 13Discovery and Pre-Clinical Stage Products 14Comparative Analysis 14Memory Impairment Therapeutics - Products under Development by Companies 15Memory Impairment Therapeutics - Products under Investigation by Universities/Institutes 16Companies Involved in Memory Impairment Therapeutics Development 17Neuralstem, Inc. 17NeuroSearch A/S 18M et P Pharma AG 19Dart NeuroScience LLC 20Omeros Corporation 21Memory Impairment - Therapeutics Assessment 22Assessment by Monotherapy Products 22Assessment by Route of Administration 23Assessment by Molecule Type 25
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comDrug Profiles 27pregnenolone succinate - Drug Profile 27Product Description 27Mechanism of Action 27R&D Progress 27NSI-189 - Drug Profile 28Product Description 28Mechanism of Action 28R&D Progress 28HT-0712 - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30Drug Targeting GPR83 - Drug Profile 32Product Description 32
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comMechanism of Action 32R&D Progress 32levetiracetam - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33HT-1067 - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 342-PMPA - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35meldonium - Drug Profile 36
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comProduct Description 36Mechanism of Action 36R&D Progress 36NS-11394 - Drug Profile 37Product Description 37Mechanism of Action 37R&D Progress 37AC-253 - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38rosiglitazone - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comGalanin Receptor 3 Program - Drug Profile 40Product Description 40Mechanism of Action 40R&D Progress 40Novel 4-8 Program - Drug Profile 41Product Description 41Mechanism of Action 41R&D Progress 41Novel 14- Program - Drug Profile 42Product Description 42Mechanism of Action 42R&D Progress 42Phosphodiesterase 4 Backup Program - Drug Profile 43Product Description 43Mechanism of Action 43
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comR&D Progress 43Novel 9-13 Program - Drug Profile 44Product Description 44Mechanism of Action 44R&D Progress 44Drug Targeting Lipoprotein Lipase - Drug Profile 45Product Description 45Mechanism of Action 45R&D Progress 45Memory Impairment Therapeutics - Drug Profile Updates 46Memory Impairment Therapeutics - Dormant Products 48Appendix 49Methodology 49Coverage 49
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comSecondary Research 49Primary Research 49Expert Panel Validation 49Contact Us 50Disclaimer 50
    • For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/15464/Memory-Impairment---Pipeline-Review,-H1-2013/
    • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com